Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara M Tolaney

Showing results (51-60 of 372) with videos related to

Pageof 38
Sort By:
Stem Cell Investigation|April 13, 2019
Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time?Romualdo Barroso-Sousa, Geoffrey I Shapiro, Sara M Tolaney
JAMA Oncology|June 30, 2018
Database Selection and Heterogeneity-More Details, More Credibility-ReplyRomualdo Barroso-Sousa, William T Barry, Sara M Tolaney
Journal of Cancer Policy|August 12, 2024
Globalization of clinical research in oncology: Status, challenges, and future directionsAna Tečić Vuger, Robert Separovic, Sara M Tolaney, et al.
JAMA Oncology|September 12, 2024
Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer: A ReviewPaolo Tarantino, Gabriel Hortobagyi, Sara M Tolaney, et al.
Nature Reviews. Clinical Oncology|June 9, 2023
Optimizing the safety of antibody-drug conjugates for patients with solid tumoursPaolo Tarantino, Biagio Ricciuti, Shan M Pradhan, et al.
Therapeutic Advances in Medical Oncology|July 25, 2018
CDK4/6 inhibition in breast cancer: current practice and future directionsSonia Pernas, Sara M Tolaney, Eric P Winer, et al.
Cancers|August 12, 2023
Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and OpportunitiesRomualdo Barroso-Sousa, Jana Priscila Pacífico, Sarah Sammons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2021
Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?Paolo Tarantino, Sara M Tolaney, Nadia Harbeck, et al.
Clinical Breast Cancer|September 2, 2008
Lymphopenia associated with adjuvant anthracycline/ taxane regimensSara M Tolaney, Julie Najita, Eric P Winer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2026
Bridging the Gap: Advancing First-Line Therapy for Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast CancerCarmine Valenza, Nancy A Nixon, Winson Y Cheung, et al.
Pageof 38

Showing results (51-60 of 372) with videos related to

Sort By:
Pageof 38
Stem Cell Investigation|April 13, 2019
Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time?Romualdo Barroso-Sousa, Geoffrey I Shapiro, Sara M Tolaney
JAMA Oncology|June 30, 2018
Database Selection and Heterogeneity-More Details, More Credibility-ReplyRomualdo Barroso-Sousa, William T Barry, Sara M Tolaney
Journal of Cancer Policy|August 12, 2024
Globalization of clinical research in oncology: Status, challenges, and future directionsAna Tečić Vuger, Robert Separovic, Sara M Tolaney, et al.
JAMA Oncology|September 12, 2024
Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer: A ReviewPaolo Tarantino, Gabriel Hortobagyi, Sara M Tolaney, et al.
Nature Reviews. Clinical Oncology|June 9, 2023
Optimizing the safety of antibody-drug conjugates for patients with solid tumoursPaolo Tarantino, Biagio Ricciuti, Shan M Pradhan, et al.
Therapeutic Advances in Medical Oncology|July 25, 2018
CDK4/6 inhibition in breast cancer: current practice and future directionsSonia Pernas, Sara M Tolaney, Eric P Winer, et al.
Cancers|August 12, 2023
Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and OpportunitiesRomualdo Barroso-Sousa, Jana Priscila Pacífico, Sarah Sammons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2021
Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?Paolo Tarantino, Sara M Tolaney, Nadia Harbeck, et al.
Clinical Breast Cancer|September 2, 2008
Lymphopenia associated with adjuvant anthracycline/ taxane regimensSara M Tolaney, Julie Najita, Eric P Winer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2026
Bridging the Gap: Advancing First-Line Therapy for Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast CancerCarmine Valenza, Nancy A Nixon, Winson Y Cheung, et al.
Pageof 38